Nonsense mutations in the vpr gene of HIV-1 during in vitro virus passage and in HIV-1 carrier-derived peripheral blood mononuclear cells  by Nakaya, Takaaki et al.
FEBS Letters 354 (1994) 17-22 
FEBS 14687 
Nonsense mutations in the vpr gene of HIV-l during in vitro virus passage 
and in HIV-l carrier-derived peripheral blood mononuclear cells 
Takaaki Nakaya”, Koh Fujinaga”, Masahiko Kishi”, Shinichi Okab, Takeshi Kuratac, 
Ian M. Jonesd, Kazuyoshi Ikuta”,* 
“Section of Serology, Institute of Immunological Science, Hokkaido University, Kita-ku, Sapporo 060. Japan 
bUniversity of Tokyo, Minato-ku, Tokyo 108, Japan 
‘National Institute of Health, Shinjuku-ku, Tokyo 162, Japan 
‘NERC Institute of Virology, Mansjield Road, Oxford, OXI 3SR, UK 
Received 9 September 1994; revised version received 19 September 1994 
Abstract Long-term, persistent infection by HIV-l is a prerequisite for the development of AIDS. However, little is known of the determinants 
required for HIV-l to cause persistence. We have reported previously that persistent infection of a T cell line by a cytopathogenic strain of HIV-l 
became increasingly likely with in vitro serial passage of the virus. DNA sequencing of the persistent strains revealed a nonsense mutation in the 
vpr gene in all isolates tested. Here, we report the development and use of a semi-quantitative PCR method to detect he vpr nonsense mutation within 
populations of virus. Our results show that vpr mutants also arise in cells during acute infection and increase progressively with serial passage of 
the virus. In addition, HIV-1-seropositive individuals were examined and found to carry the same vpr nonsense mutation at high frequency in 
virus-infected PBMC. These data are consistent with a mechanism of HIV-I persistence in vivo and in vitro in which virus cytopathogenic potential 
is lost by the build up of nonsense mutations in vpr. 
Key words: HIV-l; Accessory gene; vpr; Persistent infection; Mutation 
1. Introduction 
Generally, retroviruses are known to mutate at high rates 
[l-3]. This high mutation rate allows the selection of adapted 
virus in response to changing environmental conditions. The 
extensive genetic and antigenic variability of retroviruses also 
applies to HIV-l, the causative agent of AIDS [4-91. HIV-l, a 
member of the lentivirus subfamily of retrovirus, is highly cyto- 
pathogenic [lo]. Nevertheless, the continued presence of HIV-l 
infection has been demonstrated in all HIV- 1 -seropositive indi- 
viduals [l I]. Thus, HIV-l can remain clinically silent for a long 
period in a state of persistent infection, before the onset of 
AIDS. A characteristic feature of HIV-l strains recovered ur- 
ing the persistent period is lower cytopathogenicity when com- 
pared with strains isolated from AIDS patients [12,13]. Thus, 
there might be a positive trend towards the selection of non- 
cytopathogenic or less cytopathogenic HIV-l during persistent 
infection of host cells. 
The objective in this study was the detection of non-cytopa- 
thogenic HIV-l forms in order to assess their correlation with 
virus persistence. We showed previously that infection by HIV- 
1 carrying mutations at vif, vpr, or vpu generates persistent 
infection, whilst, by contrast, infection by wild-type HIV-l 
caused complete killing of the infected cells [14-161. In addition, 
we have shown recently that persistent infection can be gener- 
ated by wild-type HIV-l following in vitro serial passage and 
that the rate of persistent infection increased with serial passage 
[17]. However, persistently infected cells were only obtained 
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after severe cytolysis of most cells [17], indicating that passaged 
wild-type HIV-l stocks consist of mixtures, i.e. a major popula- 
tion of cytopathogenic viruses leading to effective cell killing 
and a minor population of non-cytopathogenic viruses which 
can lead to persistent infection. Sequence analysis of provirus 
genomes recovered from the persistent infections derived from 
passaged virus revealed truncation of the vpr gene caused by 
the appearance of a novel stop codon as a regular mutation, 
and to a lesser extent, by other heterogeneous mutations [17]. 
These data suggested that the generation of persistent infection 
may be linked with infection by HIV-l carrying, at least, the 
naturally occurring vpr nonsense mutation. Using a specific 
PCR procedure, we report here the increased frequency of the 
vpr mutation in a HIV-l population during serial passage in our 
in vitro cell system. In addition, the vpr mutation was detected 
at a high frequency in PBMC from HIV-l carriers confirming 
a link between the vpr truncation and persistent infection dur- 
ing virus transmission in nature. 
2. Materials and methods 
2. I. Cells and viruses 
An MT-4 derived subclone Ml0 181 was maintained in RPMI-1640 
supplemented with 10% fetal bovine serum (complete medium). The 
wild-type HIV-l was obtained from SW480 transfected with infectious 
molecular clone pNL432 [19]. 
2.2. Preparation of serial passage of HIV-I 
Serial passages of HIV-l in Ml0 cells up to 50 passages, designated 
as wt-1 to wt-50, were prepared as described previously [17]. Persist- 
ently infected Ml0 cells generated by the serial passaged virus were also 
prepared as described previously [17]. Cell clones were isolated from the 
Ml0 cells persistently infected with passage 50 by limiting dilution in 
a 96-well microplate as described previously [15]. 
2.3. Isolation of PBMC from HIV-1-seropositive subjects 
The PBMC fraction from HIV-1-seropositive subjects was prepared 
by centrifugation on Ficoll-Hypaque (Pharmacia-LKB). 
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Fig. 1. Selective PCR amplification of nonsense vpr gene. Primer design for specific amplification of the vpr with nonsense mutation is shown on 
the top. Serial ten-fold dilutions of 1 pg pWT containing wild-type vpr sequence and 1 pg pMU containing vpr with nonsense mutation were subjected 
to PCR by using five acceptor primers Pl to PS and the same donor primer as described in section 2 (bottom). The numbers 1 to 5 on the top of 
figures indicate 10e5 to 10m9 pg of plasmid DNA were subjected to PCR 
2.4. Semi-quantitative PCR analysis of HIV-I genome 
Total cellular DNAs were extracted from acutely or persistently 
HIV-l-infected cells and HIV-l carrier-derived PBMC as described 
previously [15]. The amplification of extracted DNAs was performed 
with Taq DNA polymerase (Biotech International Ltd., Australia) in 
the Perkin-Elmer Cetus automated DNA thermal cycler. Each cycle 
consisted of denaturation at 94°C for 1 min, annealing of primers at 
60°C for 2 min, and extension at 72°C for 2 min. After 30 cycles, the 
amplified DNA was analyzed on a 2% agarose gel, then stained with 
ethidium bromide. 
2.5. PCR primers 
For the amplification of wild-type vpr gene, AAGCCACCTTTGC- 
CTAGTGTTA at nucleotides 5518 to 5539 as a donor mimer and 
GTTGTCCTAAGTTATGGAGCC (Pl) at nucleotides 5891 to 5671 
as an acceptor primer were used. For the rapid assessment of the 
nonsense mutation in vpr, four other acceptor primers (P2 to P4) were 
examined. The underlined two bases in Pl were changed to ‘CT’ in P2, 
‘TT’ in P3, ‘AA’ in P4, and ‘GG’ in P5 (Fig. 1). Forthe amplification 
of the wr gene in the PBMC from HIV-l carriers, nested PCR was also 
performed by using GACATAAAAGTAGTGCCAAGAAGAA at 
nucleotides 4995 to 5019 as donor primer and TACTTACTGCTTT- 
GATGAGA at nucleotides 6051 to 6031 as acceptor primer for 1st 
PCR, followed by 2nd PCR as described above. As a control, the gag 
region of HIV-l in PBMC from HIV-l carriers was also amplified. The 
amplification of the gag gene was performed by nested PCR using 
primer sets (for 1st PCR, TTTGACTAGCGGAGGCTAGAAG at 
nucleotides 761 to 782 as donor primer and TTTGGTCCTTGTCTT- 
ATGTCCAGAATGC at nucleotides 1658 to 1631 as acceptor primer; 
and for 2nd PCR, AACAGCCAGGTCAGCCAAAATTA at nucleo- 
tides 1162 to 1184 as donor primer and ATTTAATCCCAGGATTA- 
TCCATC at nucleotides 1602 to 1580 as acceptor primer). 
3. Results 
3.1. Specific detection of nonsense mutation in vpr by PCR 
The appearance of a novel stop codon TAG in place of TGG 
at nucleotides 5670 to 5672 in vpr gene of HIV-l provirus in 
cells persistently infected with passaged HIV-l was previously 
reported [17]. In order to quantify the mutant vpr sequence in 
infected cell populations, a PCR method to amplify only the 
sequence containing the stop codon was developed. 
Five possible acceptor primers were first examined with the 
same donor primer as described in section 2. Primers Pl and 
P2 are matched to the wild-type and stop codon sequences, 
respectively, while the remaining three primers are mismatched 
with both sequences. A DNA clone (pWT) containing the vif 
to vpr region including the TGG wild-type sequence was iso- 
lated from pNL432, while a DNA clone (pMU) containing the 
vifto vpr sequence with the TAG stop codon was isolated from 
the cells persistently infected with wt-50, as described previ- 
ously [ 171. Serial lo-fold dilutions of these plasmids (low5 to 1O-9 
pg) were subjected to PCR. Primer Pl was found to amplify a 
PCR product of 174 bp from both pWT and pMU (Fig. 1). 
However, the efficiency of amplification was different. A posi- 
tive PCR reaction required one copy of pWT, while 10 copies 
of pMU. In contrast, the reciprocal result was obtained with 
primer P2. A positive PCR reaction required 10 copies of pWT 
but only one copy of pMU (Fig. 1). Thus, use of these different 
primers allows a differential detection of mutant and wild-type 
sequences dependent on the number of copies present in the 
template DNA. The P3 primer on the other hand, could amplify 
only the pMU not the pWT sequences. However, like PI, am- 
plification required 10 copies of the pMU sequence. Primers P4 
and P5 did not amplify product from pWT or pMU. Using this 
system, a semi-quantitative characterization of the proportion 
of wild-type TGG and mutant TAG sequences in a population 
was possible by using the primers Pl and P3. Next, we exam- 
ined the efficiency of detection of the mutant vpr sequence in 
mixed samples with wild-type vpr by these two primers. 
Serial tenfold dilutions, and twofold dilutions if necessary, 
T Nakaya et al. IFEBS Letters 354 (1994) 17-22 19 
0.001 0.01 0.1 1 
Ratio of pMU/(pWT+pMU) 
Fig. 2. Efficiency of detection of the vpr sequence with nonsense muta- 
tion in the mixed samples with wild-type vpr by PCR using Pl and P3 
primers. Serial tenfold dilutions, and twofold dilutions if necessary, of 
1 fig DNA samples containing pWT and pMU, in which ratios contain- 
ing pMU were 0.001, O.Ol,O.l, 0.25,0.5,0.75,0.9,0.99, and 0.999, were 
similarly subjected to PCR using Pl or P3 acceptor primer under the 
same donor primer as described in the legend to Fig. 1. After electro- 
phoresis of the PCR product, the detection rate of the DNA band by 
P3 to that by Pl was calculated by the highest dilution showing specific 
amplification. 
of 1 pg DNA samples containing different ratio of pMU and 
pWT (0.001 to 0.999) were similarly subjected to PCR analyses 
using Pl and P3 primers. The relationship between the level of 
vpr mutant sequence present in mixed samples and the detec- 
tion rate by P3 and Pl is shown in Fig. 2. The relative ratio of 
wild-type to mutant vpr sequence was calculated from the re- 
gression line drawn from the data to derive the formula: 
log Y = 0.98881ogX- 0.01197 (r = 0.9976). 
These data showed that the use of differential PCR could 
determine the level of the vpr mutant sequence in a mixed 
population of sequences and the procedure was applied subse- 
Table 1 
Ratio containing HIV-l genome with the mutant vpr sequence in Ml0 
cells acutely and persistently infected with serial passages 
HIV-l Ratio (%) containing mutant vpr sequence in the cells at 
inoculum 
Acute uhase” Persistent ohaseb 
wt-1 <l NA’ 
wt-4 0.1 1.0 
wt-12 0.4 10.6 
wt-20 13.2 100 
wt-50 13.2 100 
“Serial twofold dilutions of the DNAs extracted from the cells acutely 
infected by serial passage were subjected to PCR with primers Pl and 
P3. The results were calculated as percentage containing mutant vpr 
sequence compared with wild-type vpr sequence according to the for- 
mula from Fig. 2. 
“Serial tenfold dilutions of the DNAs extracted from the persistently 
infected cells obtained after acute infection, were similarly subjected to 
PCR. The results were also similarly shown as for acute infection. 
‘Persistently infected cells by infection with wt-1 were not available. 
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Fig. 3. Kinetics of cytopathogenic properties of serial passages of wild- 
type HIV-l. Ml0 cells were mock-infected or infected with wt-1, wt-4, 
wt-12, wt-20, and wt-50 at the same multiplicity of infection, 0.01. The 
cells were seeded at 5 xlO’/ml. The media were replaced with fresh 
medium 4 days after infection and thereafter every 3 days. The viable 
cells were counted 2 and 4 days after infection and thereafter every 3 
days by Trypan blue dye exclusion method. The results were shown by 
relative percentages of viable cell number of each infected cells, com- 
pared with that of mock-infected cells. 
quently to both in vitro and in vivo samples of DNA containing 
HIV-l. 
3.2. Increasing of HIV-l vpr mutant with serial passage 
Serial twofold dilutions of the DNAs extracted from cells 
acutely infected with different passages of HIV-l were sub- 
jected to PCR amplification with the primers Pl and P3 under 
conditions established above. In addition, serial tenfold dilu- 
tions of the DNAs from the cells persistently infected with the 
passaged virus were subjected to similar PCR amplification. 
The results are summarized in Table 1 as the percentage of the 
total population containing HIV-l genomes carrying the vpr 
nonsense mutation calculated as described for Fig. 2. In agree- 
ment with our earlier findings [17], the DNAs from the cells 
acutely infected with wt-1 did not amplify with P3 (< 2“) under 
conditions in which the same DNAs amplified up to 2” dilution 
with Pl. On the other hand, the ability to be amplified with P3 
increased gradually with the passage number of the infecting 
viral stock, i.e. the ratios of the DNA dilution showing specific 
amplification with Pl to that with P3 were 2’/2” in wt-4, 2*/2r” 
in wt-12, and 2g12’2 in wt-20, and 2’l2’* in wt-50. The percent- 
ages of genomes containing mutant vpr sequences in these 
acutely infected cell DNAs were calculated as O.l%, 0.4%, 
13.2%, and 13.2%, respectively. These percentages almost di- 
rectly paralleled the rate of generation of persistently infected 
survivor cells following infection with the differently passaged 
viral stocks (Fig. 3). These results strongly suggest that it is the 
cells infected by the minor HIV-l population carrying the vpr 
termination sequence that can survive and become persistently 
infected. In fact, PCR results from the DNAs derived from 
persistently infected cells obtained after infection with wt-20 
and wt-50 showed the equivalent amplification rates with either 
20 
the Pl or P3 primers, indicating that almost 100% of the HIV-l 
provirus in these cells carry the mutant form of ~P’PY (Table 1). 
Similarly, all 15 cell clones which were isolated from persist- 
ently infected cells that were obtained after infection with wt-50 
and were producers of infectious, but non-cytopathogenic, 
HIV-l as described previously [ 171, also showed the same PCR 
results (not shown). However, the PCR result from the DNAs 
isolated from persistently wt-4- and wt-12-infected cells showed 
that only 1% and 10.6% of the population respectively, were the 
mutant form of vpr (Table 1). 
3.3. High rate of HIV-1 vpr mutant in PBMC from HIV-l 
carriers 
PCR amplification with primers Pl and P3 was able to iden- 
tify the ratio of nonsense to wild-type vpr sequence (Table 1) 
using the formula obtained by regression line from Fig. 2. This 
Table 2 
Detection of HIV-1 vtw nonsense mutation in PBMC from HIV-1 carriers 
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result prompted us to apply the same procedure to detect the 
relative proportion of the vpr nonsense mutation in PBMC 
from HIV-l carriers. The DNA samples from 67 PBMC of AC 
and 14 PBMC of ARC/AIDS patients were serially ten-fold 
diluted, then subjected to the PCR amplification as described 
for Table 1. To control for amplifiable sequences in these sam- 
ples, amplification of a gag gene fragment was first performed 
using the nested PCR described in section 2. A total of 60167 
and 14/14 PBMC samples from AC and ARC/AIDS patients, 
respectively, were positive for the amplification of gag gene in 
undiluted total cellular DNAs (1 pg). These gag positive PBMC 
preparations were subsequently tested by the differential vpr 
PCR procedure. For these samples efficient amplification re- 
quired nested PCR using the primer sets for 1st round PCR as 
described in section 2, followed by a 2nd round PCR using 
primers Pl and P3 as for Table 1. 
HIV-1 Clinical Date for gag vpr” vPr HIV-l Clinical Date for gag VP? vPr 
carrier stage PBMC stop codonb carrier stage PBMC stop codonb 
preparation preparation 
K.T. 
T.N. 
K.R. 
N.H. 
M.C.N 
S.O. 
J.D. 
N.K. 
T.M. 
M.H. 
B.N. 
S.Y. 
W.S. 
H.J. 
T.Y. 
G.M. 
A.N. 
U.Y. 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
AC 
91.12. 9 
92. 6. 1 
91. 2. 4 
91.12. 9 
92. 6.29 
90.12.10 
93. 3. 8 
91. 5.21 
91. 6.17 
91.12. 9 
91. 4.15 
91. 1. I 
91. 3. 4 
91. 5.13 
91. 8.19 
92. 5.25 
91. 1. I 
91 3. 4 
91. 8.19 
93. 2. 8 
91. 1.28 
91. 2. 4 
91. 1.28 
92. 1.27 
92. 6. 8 
91. 3.25 
91. 9.30 
92. 6.15 
91. 5.10 
91. I. 8 
92. 6.29 
91. 9. 2 
93. 3.22 
92. 6. 8 
92. 6.15 
93. 2. 1 
93. 3.29 
91. 1. 7 
91. 9.30 
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T.H. 
O.K. 
IT. 
F.Y. 
G.Y. 
K.M. 
K.M. 
T.K. 
N.H. 
F.D. 
T.N. 
Y.S. 
EM. 
H.K. 
F.S. 
T.T. 
N.K. 
T.T. 
S.M. 
F.T. 
+ 
R.B. 
+ 
t 
t 
t 
T.G. 
U.M. 
M.S. 
AC 91. 2. 4 
91. 4. 8 
91. 8.12 
AC 91. 3. 4 
92. 7. 6 
AC 91. 4. 8 
91. 8.12 
AC 93. 4.26 
AC 91. 3. 4 
92. 1. 6 
AC 93. 4.12 
AC 90.12.10 
AC 91. 1.28 
AC 91. 2. 4 
AC 91. 1.15 
AC 92. 2.24 
AC 92. 4. 6 
AC 92. 5.25 
AC 93. 2. 1 
AC 93. 3. 8 
AC 93. 3.15 
AIDS 91. 2. 4 
92. 6. 3 
AIDS 91. I. I 
AIDS 91. I. 8 
ARC 91. 2. 4 
91. 6.10 
91. 8. 5 
ARC 91. 3.25 
91. 4. 8 
91. 5.21 
AIDS 92. 7.13 
93. 4. 5 
ARC 91. 8.26 
ARC 92. 5.25 
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“PCR amplification with Pl primer. 
“PCR amplification with P3 primer. 
“Serial IO-fold dilutions of DNA preparation (1 pg) from AC and ARC/AIDS patients were subjected to PCR amplification with gag primers, vpr 
primers for wild-type and mutant sequences (Pl) and vpr primers for only mutant sequence (P3). The results were shown as follows by the highest 
dilution showing specific amplification: -, < 1 pg; +, I pg; ++, 100 ng; +++, 10 ng; ++++, 1 ng. 
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The results (Table 2) showed that all samples were positive 
for amplification with primer Pl, while 35.0% (21160) and 
42.9% (6/14) of the PBMC from AC and ARC/AIDS patients, 
respectively, were also positive for amplification with P3 
primer. Thus, the proportion of mutant vpr sequences in the 
DNA samples tested was a significant level of the total popula- 
tion in both AC and ARC/AIDS samples. Sequential analyses 
of the level of the vpr mutant form from the same carriers 
showed dynamic changes in the HIV-l population carrying the 
nonsense sequence in vpr. Over the period of the study (about 
2 years and 5 months), the frequency of detection of the vpr 
mutation rose to 50% (17/34) in AC and 518 (62.5%) in ARC/ 
AIDS patients. 
4. Discussion 
We showed previously a correlation between the ability of 
HIV-l to initiate persistent infections and the occurrence of 
nonsense mutations in the vpr gene [17]. In particular, the 
frequency of a novel stop codon in vpr was revealed during a 
kinetic analysis of infection with in vitro serial passages of 
cytopathogenic HIV-l [17]. In this communication, it was 
shown that the HIV-l populations taken from acute infection 
contained the same mutation and that its frequency also 
increased progressively with serial passage (Table 1). In fact, 
almost 100% of the persistent HIV-l genomes generated after 
infection with wt-20 and wt-50 passages were this mutant form 
of vpr (Table 1). In contrast, only 1% and 10.6% of the 
persistent HIV-l genomes generated after infection with wt-4 
and wt-12, respectively, contained the mutant form (Table 1). 
Thus, the mechanism by which persistent infections arise 
appears to be heterogeneous when the infecting viral stock has 
a low passage history. However, HIV-l populations carrying 
the vpr nonsense mutation gradually increased with serial 
passage to become the predominant form of persisting virus, 
with persistence caused by other mutant forms present in very 
few genomes. A similar phenomenon in which mixed variants 
fail to dominate a culture during further passages has been also 
observed for vesicular stomatitis virus [20]. Consequently, it is 
likely that the Vpr truncation we have observed arises naturally 
during serial passage of cytopathogenic HIV-l and is one of the 
key determinants for the loss of cell killing that leads to the 
generation of a persistent infection (Fig. 3). This result was 
obtained by using a specific PCR technique that was able to 
differentiate between the wild-type and mutant vpr forms by 
using specific vpr acceptor primers (Figs. 1 and 2). Under the 
same PCR conditions, it was found that a significant amount 
of HIV-l with the same vpr nonsense mutation was identified 
in 50% and 62.5% of the wild-type vpr sequence-positive AC 
and ARC/AIDS patients, respectively (Table 2). This result 
supports the hypothesis that a significant population of HIV-l- 
seropositive individuals carry HIV-l with the vpr mutation 
which might be a marker for the population of HIV-l in the 
persistent state. In addition, sequential analyses showed a 
varying amount of the same nonsense vpr sequence in the same 
individual (Table 2) over time, indicating an extraordinarily 
dynamic flux in the vpr gene structure of persistent HIV-l. In 
fact, in the three among five rhesus monkeys infected with vpr 
mutant (conversion from the ATG start codon of the vpr gene 
to TTG) of SIV, similar reversion of the TTG sequence to ATG 
was also observed 4 to 8 weeks post-infection, while no vpr 
revertants were found over the entire 66 weeks of observation 
in the other two animals which did not develop progressive 
disease [21]. 
Investigations of the accessory genes of HIV-l have been 
limited, partly due to the difficulties of readily measuring their 
functions by method using simple reporter gene systems such 
as has been possible for tat and rev [22,23]. Mutational analysis 
of HIV-l vpr has shown that mutant grew significantly more 
slowly than wild-type HIV-l [24]. In addition, vpr mutation of 
pNL432 was shown to decrease the killing of MT-4 [14,16] and 
H9 [25] cells. However, the molecular mechanism of this gene 
product is not clear at present. Recently, it was shown that the 
p6 region in Gag precursor protein is required for 
incorporation of Vpr protein into HIV-l virions [26,27]. 
Subcellular fractionation studies have also suggested that a 
nuclear localization domain, present in Vpr, may aid transport 
of the viral preintegration complex to the nucleus as deletion 
of the carboxyl-terminal 19 amino acid arginine-rich sequence 
impaired Vpr nuclear localization [28]. Our model cell system 
which permits the generation of persistently infected cells after 
infection with vpr mutant [17] may be particularly useful for 
understanding the exact molecular mechanisms of the vpr gene 
product. 
Analysis of the vpr sequence present in replication-competent 
HIV-l populations in the PBMC from HIV-l carriers is 
necessary to discriminate the persistent from latent forms of 
HIV-l. In addition, a sequential study on the vpr sequences 
present in PBMC during progression from AC to AIDS is 
required for understanding the possible evolution from 
accumulated HIV-l with nonsense vpr mutation showing non- 
cytopathogenicity to wild-type HIV-l showing cytopathogenic 
potential. 
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